It has been a very busy month so far here in Los Angeles. We have a lot to cover and it is important that all shareholders receive this information.
In this video update, Matthew brings us up to speed on developments to date in January 2020.
Some of the topics Matthew touches on in the video are:
-
Status of the Custom Bed Bug Acquisition.
-
Announcement of Nature-Cide making the shortlist of approved pesticides for the cultivation of industrial hemp in the state of Kentucky.
-
A statement that production begins on CBD Formulation of the Malibu Brands Pacific Pain Relief Cream.
-
The introduction of Bugly, the first at-home retail membership for an all-natural “Do It Yourself” pest control program, that is a private label partnership with Nature-Cide.
-
Journal of the Florida Mosquito Control Association published a study showing the results of a two-year comprehensive study testing the efficacy of 25(b) products alongside the top three global pyrethroid products. The results are astonishing.
-
Status of the pesticide toxicology testing overview.
-
Review of product retail positions and status update on the 2020 inventory needs for all retail brands.
-
Statement regarding Glendale Securities' position with the Company in preparation for the next steps after the potential acquisition.
-
Status of moving the Reg. A+ offering away from StartEngine onto our own independent platform and the launch of a new Regulation Crowdfunding Offering that will be run and overseen by the StartEngine Broker-Dealer Division and run on their platform.
Update:
It has been a busy and productive start to the year for the Company. Again, we are thankful and very appreciative for all of your support and attention. Our Management expects to accelerate the Company with both product and service revenue goals while raising the capital needed to potentially position the Company to engage with the Investment Banking community and potentially list the Company on a national exchange. Everyone is working harder than ever to continue the expansion of the Company, as well as find liquidity for our shareholders in both the short and long term. We are hopeful that all of you are just as excited as all of the Med-X staff members and will continue to support our mission in the efforts of making a difference everyday and sharing our work with family and friends to help the cause move forward in a more rapid manner.
Acquisition Strategy
The Custom Bed Bug acquisition is not finalized but it is close. Legal is tying up the loose ends on both sides. These things take time and we are grateful for all the hard work that has gone into this on both sides. Anything can happen with these things, and the deal won’t officially be done until we announce it. Once this is finalized we will be moving swiftly to start the talks with our other targets who are standing by waiting for engagement. This is the service piece of the business that the investment bankers that we are speaking with, are waiting for Med-X to finalize.
Hemp Farming
We are excited to announce that the Kentucky Department of Agriculture has listed both the Nature-Cide All Purpose Concentrate and the Nature-Cide Outdoor as approved registered products for the cultivation of industrial hemp. This again solidifies our national position in the Cannabis and Hemp markets as a leading insecticide solution. Kentucky is a leading producer in US Industrial hemp and we see this as the important list to be on as other states follow Kentucky’s lead in regulating hemp farming in the US. We also believe that the Kentucky regulatory system will also be considered when, and if, the Federal Government opens the doors to THC cultivations with the seemingly imminent descheduling of Marijuana from the Controlled Substance Act.
Click Here to Download the Kentucky Department of Agriculture Document
Malibu Brands
We are in multiple discussions with local contract manufacturing partners in regard to the mass production of the Malibu Brands products. This also includes the official launch of the Pacific Pain Relief Cream with added CBD. The Management team is in talks with several financial institutions who will potentially become critical partners for us as we begin to sell the Hemp-derived CBD products. The Company is also working diligently to get both the CBD Pain Relief Cream and the Non-CBD Pain Relief Cream registered with the FDA. This is a long process but if and when we are able to finalize this, we are confident our Healthcare Distribution partners will begin taking on that line of products as well placing the products into OTC pharmacies.
Nature-Cide Breakout to Retail
We are also proud to announce our partnership with the team from Bugly, the first at-home retail membership for an all-natural “Do It Yourself” pest control program, that is a private label partnership with Nature-Cide. The Bugly project will be our first major step to provide the products directly to the consumer. We have to be strategic on how we enter the retail market as to not disrupt our positions in Professional Sectors. We believe this approach and this model have a great chance to be very successful. The model is seeing success in other DIY products like lawn care and we are excited to see how it performs as the insect season picks up.
Nature-Cide Mosquito Efficacy
The Nature-Cide products have a great deal of efficacy to back up their claims and as a multi-state registered pesticide, we are forced to prove certain efficacy in order to get our labels registered. These products have been tested by professors and scientists on several occasions. But when we were recently informed about the latest findings from a two-year report published in the latest journal of the Florida Mosquito Control Association, we nearly fell out of our chairs. We knew the Nature-Cide products performed well on mosquitoes but we were thrilled to read that Nature-Cide was found to be the top-performing mosquito insecticide tested, regardless of its botanical status. Globally the fight to control mosquitos is the top public health priority with 17% of all infectious diseases transmitted globally are vector-borne. Mosquito vector control is the holy grail of pest control. Mosquito vector control is typically the responsibility of local, county, regional and federal municipalities. The scope and importance and potential implications of this study are not yet fully set in with the management team. The products hands down blew away our top green competitor “Essential IC3” and also outperformed, at all mixture rates, all of the top three biggest global sellers of synthetic pyrethroid mosquito insecticides. This was a third party scientific study done without our knowledge and it deserves everyone’s close attention. Please read the report. Below are the abstracts from both of the individual studies using both formulations.
The trouble with Controlling Mosquitoes is the balancing act you have with the risk of spraying the chemicals. The chemicals can only be sprayed so much or else the risk of poisoning and polluting the environment become too high. With a 25(b) botanical products like Nature-Cide, you can apply the product freely with little to no risk of environmental and human contamination. This could be the break we have been waiting for. The last step is to finalize the findings with toxicology reports to confirm that the products do not pose a risk to water ecology and non-target pests like pollinators.
Below we have included the Abstracts from the report and we highly suggest you download the full report and reviews, to see the results and the positive comments for yourself.
EVALUATION OF PYRETHROID AND BOTANICAL BARRIER INSECTICIDES AGAINST AEDES ALBOPICTUS IN THE LABORATORY AND FIELD
STEVEN T. SMOLEROFF, CHRISTOPHER S. BIBBS, AND RUI-DE XUE
Anastasia Mosquito Control District, 120 EOC Drive, St. Augustine, FL 32092
Subject Editor: Seth Britch
ABSTRACT
Outdoor residual insecticide applications are useful for preventing or reducing mosquito populations at focal areas. Until recently, pyrethroids have been the only option for barrier sprays in mosquito control. In this study, three pyrethroid (Onslaught, Cyzmic CS, DeltaGard) and two botanical (Nature-Cide, Essentria IC3) outdoor residual insecticides were comparatively tested at low, mid, and high label rates against adult Aedes albopictus in both laboratory bioassays and field trials in St. Augustine, FL, from May-August 2017. Bioassays indicated NatureCide and Cyzmic CS were the most toxic across all three dilution ratios followed by DeltaGard, Onslaught, and Essentria IC3, respectively. In field trials Nature-Cide and Onslaught were the only products that reduced mosquito abundance at the low rate. However, at the mid rate Nature-Cide and Onslaught caused ~90% percent reduction of adult female Ae. albopictus in the field, the highest of all tested products. The performance of DeltaGard (79% reduction in field counts), Essentria IC3 (64%), and Cyzmic CS (36%) in the field were not similar to the laboratory results. The universally high performance of Nature-Cide indicates that mosquito control operations should expand consideration to botanical based insecticides for field operations.
SEMI-FIELD ULV EVALUATION OF AN ALL-PURPOSE BOTANICAL INSECTICIDE CONTAINING CEDARWOOD AND CINNAMON OILS AGAINST ADULT AEDES AEGYPTI
CHRISTOPHER S. BIBBS, KATHY SHIRLEY, DENA L. AUTRY, AND RUI-DE XUE
Anastasia Mosquito Control District, 120 EOC Drive, St. Augustine, FL 32092
Subject editor: Eva Buckner
ABSTRACT
Public health mosquito control operates with only two classes of mosquito adulticides: pyrethroids and organophosphates. Recent work improving the emulsification of essential oils has increased the potential for development of plant derived active ingredients. There is a growing body of literature on essential oils for various roles in mosquito management. Nature-Cide Pest Management (NCPM), a product available in private and commercial home pest control, uses a mixture of 25.3% cedarwood oil and 12.7% cinnamon oil as a Federal Insecticide, Fungicide, Rodenticide Act (FIFRA) exempt insecticide for both indoor and outdoor use. Recent investigations by the Anastasia Mosquito Control District of St. Johns County have found other FIFRA exempt products to be effective as a residual spray on vegetation. In continuing the exploration of botanical insecticides, NCPM was used in ultra-low volume (“ULV”) tests against Aedes aegypti (L.) within its 35-122 ml per L of water label rate. Applications at 35 ml/L resulted in 60-70% knockdown after 1 hr and mortality after 24 hr. Increasing the rate to 70 ml/L resulted in 100% knockdown and mortality across all replications. Crystalline precipitation of the microemulsion was observed in mix tanks after standing for at least 2 wk, but it was not apparent that the efficacy of the product was reduced as a consequence. Cedarwood oil and cinnamon oil are a beneficial combination for ULV adulticiding against mosquitoes and could have a beneficial role for integrated mosquito management.
Retail Inventory
Purchase Orders are already starting to roll in for Thermal-Aid and Nature-Cide. With word of the report about Nature-Cide starting to spread in social media, we need to make sure our inventory levels are adequate to fulfill these growing pains. Everything is seemingly ramping up across the board and we are going to need to keep up with the demand of positioning our high margin products over the next few months.
Toxicology Reports
Several countries have been knocking on the door for months waiting for the Nature-Cide Toxicology reports. When the reports are completed, we will begin engagements and enter most of the other countries to continue the growth of the Nature-Cide brand world-wide. These reports are costly and require all of our focus to get this down, as we believe the rewards to be very beneficial for the Company. The need for the Nature-Cide products is much stronger overseas than in the US. Pesticide regulations are far more strict in all other countries vs. the US. The sooner we can complete the toxicology studies, the faster these products can go to Southeast Asia, Africa and South America where the governments of these countries spend hundreds of millions of dollars spraying toxic chemicals to maintain public health requirements on mosquito control and pest management.
Listing
Glendale Securities has delivered the 15c2-11 information requirement package and we have several investment banks sitting on the sidelines waiting patiently for the Custom Bed Bug acquisition to be finalized. As soon as we hit our revenue milestones and have the capital on hand with a commitment from an Investment Bank, we plan to pull the trigger and list on an exchange when the timing is right and the market conditions are favorable.
Crowdfunding Platforms
Very soon the Company will be pulling its Reg. A+ Offering off of the StartEgine platform and replacing it with a Regulation Crowdfunding Offering (“Reg CF”). We are doing this to fulfill our commitment to our broker-dealer NMS Capital and to allow ourselves the flexibility needed to go out and continue raising capital, with multiple Broker-Dealers by our side. This is the best move for the Company at this time. We are hopeful that the technology we have built for our new capital-raising platform will offer our investor relations and marketing team the transparency and flexibility needed to raise the capital rapidly that the Company needs. The Reg CF will still allow individuals who prefer the StartEngine Platform to continue to invest. However, moving forward in the coming days, all new Reg A+ investments will be processed via our new, independent platform on medxinvestor.com.
As you can see, there are a lot of great things going on here at the Company, and we are confident in the direction we are headed. We need every staff member, associate and shareholders’ focus to share our mission of making a difference every day with friends and family so as to expand the work we are doing world-wide.
I cannot thank each and every shareholder enough. We want to hear from you directly. If you have ideas or know people in states that can help our efforts, please call us. Together we can continue making a difference every day.
Sincerely,
Matthew Mills
DISCLAIMER AND FORWARD-LOOKING STATEMENTS
The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company.
This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.